SCHEMBL5574766

SCHEMBL5574766

C=CC(=O)NNC(CCC(=O)O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 6/20 0.48
NAALAD2 Q9Y3Q0 4/20 0.48
RIMKLA Q8IXN7 1/20 0.48
GGH Q92820 1/20 0.42
FNTA P49354 2/20 0.41
FNTB P49356 2/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
BLM P54132 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
TET2 Q6N021 2/20 0.36
KDM4A O75164 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5574761 1.00 FOLH1 (0.48) FOLH1NAALAD2RIMKLAGGHFNTA
SCHEMBL28875871 0.86 KMT2A (0.40) FOLH1NAALAD2RIMKLAFNTAFNTB
SCHEMBL28875868 0.86 KMT2A (0.40) FOLH1NAALAD2RIMKLAFNTAFNTB
SCHEMBL9382037 0.81 FOLH1 (0.62) FOLH1NAALAD2RIMKLAGGHFNTA
SCHEMBL29013590 0.81 FNTA (0.38) FNTAFNTBTSHR
SCHEMBL29013593 0.81 FNTA (0.38) FNTAFNTBTSHR
SCHEMBL5437088 0.81 FOLH1 (0.62) FOLH1NAALAD2RIMKLAGGHFNTA
SCHEMBL5437090 0.81 FOLH1 (0.62) FOLH1NAALAD2RIMKLAGGHFNTA
SCHEMBL15361783 0.80 FOLH1 (0.60) FOLH1NAALAD2RIMKLAGGHFNTA
SCHEMBL31139984 0.79 TGFBR1 (0.40) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070009441-A1 Biodegradable nanoparticles MOLECULAR THERAPEUTICS, INC. (US) 2007-01-11 US claimed
WO-2006010083-A2 BIODEGRADABLE NANOPARTICLES MOLECULAR THERAPEUTICS, INC. (US) 2006-01-26 WO claimed
CN-115612009-B Hydrogel tissue adhesive based on dicarboxy amino acid and preparation method thereof 西安交通大学 2024-02-13 CN disclosed
CN-115612014-B Biological tissue adhesive capable of being adhered when meeting water and preparation method thereof 西安交通大学 2024-02-13 CN disclosed
US-20070009441-A1 Biodegradable nanoparticles MOLECULAR THERAPEUTICS, INC. (US) 2007-01-11 US disclosed
WO-2006010083-A2 BIODEGRADABLE NANOPARTICLES MOLECULAR THERAPEUTICS, INC. (US) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070009441-A1 Biodegradable nanoparticles CD47, CD63, ECPAS FOLH1 83/4885NAALAD2 669/4885RIMKLA 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.